Charcot-Marie-Tooth 1A concurrent with anaplastic ependymoma in a toddler: when an acute event unmasks a chronic condition

Özet

We report a 14-month-old toddler admitted to the Pediatric OncologyDepartment after surgical resection of supratentorial anaplastic ependymoma.The child was treated with International Society of Pediatric OncologyEpendymoma II 2015 chemotherapy protocol (vincristine, carboplatin,cisplatin, cyclophosphamide and methotrexate). At the end of the first cyclethe child presented with symptoms such as unsteadiness and ataxic gait alongwith decreased motor and sensory action potentials of the limbs. As the fatherof the child was diagnosed with Charcot-Marie-Tooth 1A disease, a geneticanalysis of the PMP22 gene was performed confirming the diagnosis of CharcotMarie-Tooth 1A in the child, too. This case gently reminds the possibilityof vincristine-induced neurotoxicity and underscores the significance of anappropriate neurological assessment before vincristine initiation.